Physician profile
David B Hevert
NPI 1184700775
$9,231.19
in general payments reported to CMS, 2019-2025
57 companies · $1,264 in 2025
The $1,264 reported for 2025 was more than what 88% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,448 · 2020: $1,486 · 2021: $1,656 · 2022: $1,168 · 2023: $1,108 · 2024: $1,101 · 2025: $1,264.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,467 · Education: $6.15.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,467.13 |
| Education | $6.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,061.16 | 2019-2022 | |
| Amgen INC. | $806.70 | 2019-2025 | Repatha, Evenity, Krystexxa |
| Abbvie INC. | $759.31 | 2021-2025 | |
| Pfizer INC. | $661.55 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $594.37 | 2019-2024 | |
| Glaxosmithkline, LLC. | $520.42 | 2019-2023 | Arexvy, Shingrix, Trelegy Ellipta |
| Amarin Pharma, INC. | $390.05 | 2019-2023 | |
| Astellas Pharma US INC | $327.42 | 2019-2025 | Veozah |
| Astrazeneca Pharmaceuticals Lp | $305.36 | 2021-2025 | Breztri, Wainua, Airsupra |
| Abbott Laboratories | $272.71 | 2020-2025 | Aveir, Freestyle Libre 2, Freestyle Libre 3 |
| Kvk-Tech, INC. | $262.19 | 2019-2024 | |
| Otsuka America Pharmaceutical, INC. | $249.89 | 2024-2025 | Rexulti |
| Boston Scientific Corporation | $194.67 | 2019-2025 | Watchman Flx, Watchman Access System |
| Merck Sharp & Dohme LLC | $190.79 | 2019-2025 | Verquvo, Gardasil 9, Capvaxive |
| Novo Nordisk INC | $183.59 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
Show all 57 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Hevert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.